Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Illinois Program Uses Text Messaging To Encourage HIV Testing
The Illinois Department of Health has launched a program, "Text 2 Survive," that uses cell phone text messaging to encourage residents to be tested for HIV, NBC Chicago reports. Through the program, individuals can send a text message to a designated number with their ZIP code and receive a reply that provides the nearest HIV testing center"s contact information. To promote the program, through July 1, individuals who send a text to the program or forward the reply message to others will be entered into a sweepstakes for a chance to win a $50 gift card. Those who confirm they have been tested have an opportunity to win an additional $200 gift card (NBC Chicago, 6/17).
generic viagra online
Mutations Extending Lifespan Induce Expression Of Germline Genes In Somatic Cells
In the sense that organisms existing today are connected through a chain of life - through their parents, grandparents and other ancestors - almost a billion years back to the first animals of the pre-Cambrian era, an animal"s reproductive cells can be considered to be immortal. These germline cells generate their offspring"s somatic cells - other cells involved in all aspects of growth, metabolism and behavior, which have a set lifespan - and new germline cells that continue on, generation after generation.
News of the day
Unique Collaboration Between TB Alliance And Tibotec To Accelerate Tuberculosis Drug Development
A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec Inc., (Tibotec), a global pharmaceutical company, has been announced at the Pacific Health Summit in response to the urgent need to accelerate the discovery and development of new drugs to fight tuberculosis (TB).
Nutrition

UPCI Joins ExCell Research Study Using Stem Cells For Leukemia And Lymphoma Patients

The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study. The phase III study is assessing the safety and efficacy of StemEx®, an investigational product derived from stem cells, as an alternative treatment to bone marrow transplants for hematological malignancies, including leukemia and lymphoma. StemEx is a graft of expanded stem/progenitor cells taken from a single unit of umbilical cord blood and then transplanted in combination with non-expanded cells from the same unit. "I am extremely pleased UPCI has the opportunity to be a part of this study," said Mounzer Agha, M.D., clinical director of UPCI"s Hematopoietic Stem Cell Transplant Program. "Using umbilical cord blood stem cells instead of a traditional bone marrow transplant opens tremendous treatment possibilities for patients with diseases like leukemia and lymphoma." Bone marrow transplantation is a life-saving treatment for many types of leukemia and lymphoma. However, more than half the number of patients in need of a transplant can"t find matching bone marrow donors. Cord blood could be an alternative of choice. Previous research has shown that umbilical cord blood stem cells offer a viable therapeutic option for leukemia and lymphoma patients without the necessity of a matched donor. Umbilical cord blood has two important advantages-it is a readily available for stem cells and it has a lower matching requirement for patients. With StemEx®, the cord blood unit is enriched with stem cells, which are critical for a successful transplantation. "We are pleased to work with the able and highly experienced team at UPCI led by Dr. Agha. They join an extraordinary group of cord blood cancer centers currently recruiting patients for the ExCell trial. Everyone on the international ExCell clinical team shares the same goal-to validate the therapeutic potential of StemEx as a treatment for blood cancers," said David Snyder, M.D., vice president of clinical development at Gamida Cell. The University of Pittsburgh Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009